Brief: Trevi Therapeutics Provides Business Updates

Trevi Therapeutics

04/01/2024 12:40

Jan 4 (Reuters) - Trevi Therapeutics Inc  TRVI.O :
    * TREVI THERAPEUTICS PROVIDES BUSINESS UPDATES
    * TOPLINE DATA FROM PHASE 2A RIVER TRIAL IS EXPECTED IN
SECOND
HALF OF 2024
    * HUMAN ABUSE POTENTIAL STUDY IS ACTIVE AND DOSING IS
EXPECTED TO
BEGIN IN JAN 2024, WITH TOPLINE DATA EXPECTED IN 2H OF 2024
    * PHASE 2B CORAL TRIAL FULL ENROLLMENT IS EXPECTED THIS YEAR
AND
TOPLINE RESULTS ARE EXPECTED IN FIRST HALF OF 2025
    * PHASE 2B CORAL TRIAL INCLUDES A SAMPLE SIZE RE-ESTIMATION
WHICH
IS EXPECTED TO OCCUR IN SECOND HALF OF 2024

Source text for Eikon:  ID:nPn8J8PwBa 
Further company coverage:  TRVI.O 

 ((Reuters.Briefs@thomsonreuters.com;))